Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva’s Rosy View For A Happy Union With Allergan Generics

Executive Summary

The company provided updated mid-term guidance for the combined company, net revenues of $26.7bn to $27.8bn and EBITDA of $10.7bn to $11.5bn in 2019. The deal is expected to close any day, management assured investors.

You may also be interested in...



Stockwatch: Teva, Biogen, Ionis, Sage And The Art Of Strategic News Placement

Earnings announcements from Teva and clinical trial results from Biogen, Ionis and Sage have turned out to have quite different interpretations in retrospect. Exciting news can sometimes look more like a vehicle for strategically timed stock promotion than a genuine material event.

Teva Advancing Two Advair Generics With Late 2017 Target

Teva will move forward an internal generic Advair candidate and one acquired from Allergan to improve its chances of getting an interchangeable version of the market-leading asthma drug approved by FDA.

Teva Embarks On New Phase With FTC Clearance Of Allergan Generics

Teva said the deal will close the first week of August, after agreeing to sell assets related to 79 pharmaceutical products to gain FTC clearance.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel